KRAS and non-small cell lung carcinoma: Continuing study is needed to compare real-world outcomes for patients with and without brain metastases and to assess whether KRAS mutation status has an impact on the survival of patients with metastatic NSCLC who are treated in first-line with ICI-chemotherapy.